- Author:
Rong-Jie LIN
;
Zi-Zhuo SU
;
Shu-Min LIANG
;
Yu-Yang CHEN
;
Xiao-Rong SHU
;
Ru-Qiong NIE
;
Jing-Feng WANG
;
Shuang-Lun XIE
1
;
Author Information
- Publication Type:Journal Article
- MeSH: Coronary Disease; pathology; Fibroblasts; physiology; Fibrosis; pathology; Heart Failure; pathology; Humans; Hypertension; pathology; Myocardium; pathology
- From: Chinese Medical Journal 2016;129(3):326-331
- CountryChina
- Language:English
-
Abstract:
OBJECTIVEIt is revealed that circulating fibrocytes are elevated in patients/animals with cardiac fibrosis, and this review aims to provide an introduction to circulating fibrocytes and their role in cardiac fibrosis.
DATA SOURCESThis review is based on the data from 1994 to present obtained from PubMed. The search terms were "circulating fibrocytes " and "cardiac fibrosis ".
STUDY SELECTIONArticles and critical reviews, which are related to circulating fibrocytes and cardiac fibrosis, were selected.
RESULTSCirculating fibrocytes, which are derived from hematopoietic stem cells, represent a subset of peripheral blood mononuclear cells exhibiting mixed morphological and molecular characteristics of hematopoietic and mesenchymal cells (CD34+/CD45+/collagen I+). They can produce extracellular matrix and many cytokines. It is shown that circulating fibrocytes participate in many fibrotic diseases, including cardiac fibrosis. Evidence accumulated in recent years shows that aging individuals and patients with hypertension, heart failure, coronary heart disease, and atrial fibrillation have more circulating fibrocytes in peripheral blood and/or heart tissue, and this elevation of circulating fibrocytes is correlated with the degree of fibrosis in the hearts.
CONCLUSIONSCirculating fibrocytes are effector cells in cardiac fibrosis.